The Joint (JYNT) investor relations material

Executive summary

• Transformation strategy Joint 2.0 is on track, focusing on refranchising and operational efficiency, with completion expected by year-end 2025.

• Management team strengthened with healthcare and franchise experience; significant reduction in corporate-owned clinics from 135 to 48 by year-end 2025.

• Shift to a pure-play franchisor model underway, aiming for improved operating leverage and capital-light operations.

• Enhanced marketing and patient acquisition strategies, including a pivot to pain relief messaging, national campaigns, and a new mobile app with high patient engagement.

• Capital allocation prioritized for growth investments and share repurchases.

Financial highlights

• Q4 2025 revenue from continuing operations increased 3.1% year-over-year to $15.2 million; full-year revenue reached $54.9 million, up from $52.2 million in 2024.

• Q4 2025 consolidated adjusted EBITDA rose 7.8% to $3.6 million; full-year adjusted EBITDA up 13.9% to $13.0 million.

• System-wide sales for Q4 2025 were $139.6 million, down 3.9% year-over-year; full-year system-wide sales were $532.4 million, up 0.4%.

• Consolidated net income for Q4 was $1 million; full-year net income $2.9 million, reversing a $5.8 million loss in 2024.

• Unrestricted cash at year-end 2025 was $23.6 million; no funds drawn on $20 million credit line.

Outlook and guidance

• 2026 system-wide sales expected between $519 million and $552 million.

• Comp sales guidance for 2026 ranges from -3% to 3%; consolidated adjusted EBITDA expected between $12.5 million and $13.5 million.

• Net clinic count projected to decline in 2026 as portfolio is optimized for stronger operators; targeting 30–35 new franchised clinic openings.

• Long-term potential for over 1,800 clinics in the U.S.; 2026 continuing operations expected to be more profitable.